Page last updated: 2024-08-24

topotecan and pf 00299804

topotecan has been researched along with pf 00299804 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Z; Fu, L; Guo, X; Luo, M; To, KKW; Wang, F; Wang, X; Yan, S; Zhang, J1

Other Studies

1 other study(ies) available for topotecan and pf 00299804

ArticleYear
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Journal of experimental & clinical cancer research : CR, 2018, Feb-20, Volume: 37, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Membrane; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Mice; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Topotecan; Xenograft Model Antitumor Assays

2018